
TECMINE



Final Report


Diabetes - Insulin - Care Patent and Technology Landscape

8.12.2017

ARTIFICIAL INTELLIGENCE


Powered Innovation

- Overall patenting in Diabetes Care Wellness space is increasing
- Technologal change is very rapid and intense. Diagnostic technologies are merged with computer and software technologies.
- Range of smaller emerging technologies and business domains are visible (AI, early diagnosis, predictive care)
- Old and new firms compete intensely.
 The industry patents are applied for by a wide range of companies, old and new, large and startups
- Patents are increasingly important for new business and growth areas



Total patenting in THE FINAL
PATENT LANDSCAPE is about
6 000 annual new patents in 2017


- Growth Areas are specific, small and emerging. They include:
 - AI and Machine Learning for Diabetes. This group involves much "wearable" type of inventions.
 - Early Detection of Diabetes. This includes also a range of "life style" related solutions.
 - Solutions for type 2- Diabetes. This group includes medical diagnosis and treatment inventions, but increasingly also "life style" related solutions.
- Competition is focussed on highly specialized technology and business segments.
- In contrast, competition in established or old technology areas is markedly slow or declining.



Rapid rise of patenting in AI and Machine Learning Diabetes Solution.


Predictive and intelligent wellness monitoring is a rapid growth area.

- Within established technology and business areas, large incumbent firms have cemented their positions with very large patent portfolios.
- In emerging technology and business domains new and small firms have potential to capture industry leadership.
- The balance between large-incumbent firms vs new-starups is different depending on the pace of technology innovation in the business domain.



FITBIC INC, an industry outsider and wearable start-up, is the leading inventor for solutions to identify pre-diabetic conditions.

- Patenting is declining by large firms, in general.
- This, together with clearly emerging new technology areas, suggests that large firms are trying to adapt to the new competitive landscape.
- The role of small, innovative and, focussed firms is likely to be strengthened in the near future.
- An example is the Roche Group.



Diabetes patenting by Roche Group is declining, but Roche Diabetes shows strong increase in patenting emerging technologies

- M&A and venturing activity by large firms will increase in the near term.
- Digitalization is driving this trend
- This will impact technology and start-up strategies, as well as available VC funding.
- The trend is likely to continue for the next
 2-4 years

mySugr joins the Roche Family

JUNE 30, 2017 BY

This is a momentous day for any startup, but for a team on a mission it's even greater. Today we're proud to announce that we're joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes.

New Abbott diabetes deal is a "missed opportunity" for DexCom

By ARUNDHATI PARMAR

■ 1 Comment / Jul 13, 2017 at 1:52 PM

DexCom is the unrivaled king of the CGM market especially as it relates to various artificial pancreas development efforts.

A new deal between Abbott and startup Bigfoot Medical may be the beginnings of future competition for the San Diego CGM maker.

Abbott Laboratories announced Thursday that it is teaming up with Milpitas, California-based Bigfoot to develop diabetes management systems that would integrate Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. Terms of the deal weren't disclosed

- Key technologies in Diabetes Care are undergoing rapid change. Large firms have cemented their leadership in old technologies, but face tough competition by startups in novel areas, such as AI / Machine Learning / Wearables / Life Style / Pre-diabetes solutions.
- Patenting is driven by increasing inventive effort in specialized technology areas
- Successful and innovative companies must demonstrate ability to exploit emerging innovation frontiers. Old technology areas are slow in their dynamics, indicating low future potential.

Roche Acquires Digital Diabetes Tech Startup

Mon, 07/03/2017 - 10:55am 1 Comment by Ryan Bushey - Digital Editor - 💆 @R_Bushey

Johnson & Johnson's LifeScan Sued By Decision Diagnostics Over Glucose Test Strip Patents

Published: Mar 17, 2016

TEQMINE APPROACH

STAGE 1

12 million USPTO / EPO / PCT patents text-mined for "diabetes" OR "insulin" in patent full-text. Data 1.1.1990-31.9.2017 (USPTO) and 1978-31.9.2017 PCT/EPO. Records: 395,363

STAGE 2

Records classified into 10 technology and business areas with TEQMINE AI solution.

STAGE 3

Topic 3 identified as high-priority area. Select all patents < 0.30 weight for Topic 3. **Records=73,695**


STAGE 4

Records classified into 15 Topic Areas.

High accuracy identification of Client interest areas.

Network visualization of patent landscape and final analysis.

Online-Results and Tools





EVALUATING QUALITY Round 1

Method, system and computer readable medium for assessing actionable glycemic risk

Abstract

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.

Classifications

A61B5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor

View 5 more classifications

WO2016133879A1 WO Application Find Prior Art Application number: PCT/US2016/018027 Other languages: French Inventor: Stephen D. Patek Original Assignee: University Of Virginia Patent Foundation

Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device

Abstract

Methods for performing a structured collection procedure by utilizing a collection device are disclosed herein, in which a collection procedure is initiated for performing one or more data collections for one or more data event instances occurring according to a schedule of events. Each data event instances comprises a data collection pertaining to a biomarker to be performed according to one or more conditions of an adherence criterion. Each data event instance is determined to be successful or unsuccessful on the basis of actual performance of the data collection and meeting certain conditions of the predetermined adherence criteria for the data event instance. Contextual information for successful data collections is generated and a data file generated for storing records relating to successful data collections. For unsuccessful data event instances, substitute data relating to data collections performed separately from the collection procedure are included in the data file records for the collection procedure if the substitute data is determined to meet conditions of the predetermined adherence criterion for the corresponding data event instance.

Images (35)











US20140365534A1
US Application

Download PDF Find Prior Art

Legal status: Pending
Application number: US14469221

Inventor: Steven A. Bousamra , Abhishek Soni
Current Assignee: Roche Diabetes Care Inc
Original Assignee: Roche Diagnostics Operations Inc

Priority date: 2008-12-23

Filing date: 2014-08-26

Publication date: 2014-12-11

EVALUATING QUALITY Round 1

```
14469221, Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device, Roche Diagnostics, 2014
W02012089318A1, Methods of selecting diabetes therapy regimens, Roche Diabetes, 2012
W02016133879A1, Method, system and computer readable medium for assessing actionable glycemic risk, U Virginia, 2016
15063893, Method and system for recommending a set of insuling dosages for a patient, Quattro Folia Oy, 2017
```

- All high relevance patents score very high in TOPIC 3
- TOPIC 3 chosen as priority.
 205,578 records have received weith in Topic 3.
- All patents with weight >= 0.25 in Topic 3 chosen for round 2.
- Total records = 73,695

| + doc_number_1 | topic | weight | |
|----------------|-------|-----------------|--|
| 14469221 | 3 | 0.936508356376 | |
| 14469221 | 7 | 0.0433857135235 | |
| 14469221 | 8 | 0.0190862155859 | |
| 15063893 | 3 | 0.878024052943 | |
| 15063893 | 7 | 0.118286633196 | |
| W02012089318A1 | 3 | 0.845680813128 | |
| W02012089318A1 | 7 | 0.143484636468 | |
| W02016133879A1 | 3 | 0.753415166641 | |
| W02016133879A1 | 7 | 0.142952058805 | |
| W02016133879A1 | 8 | 0.0729265449237 | |
| W02016133879A1 | 10 | 0.0182467011325 | |
| + | | | |



EVALUATING QUALITY Round 2

| + | + | + |
|--------------|-------|-----------------|
| doc_number_1 | topic | weight |
| 14469221 | 3 | 0.121816136539 |
| 14469221 | 5 | 0.197535887831 |
| 14469221 | 9 | 0.0629149546361 |
| 14469221 | 10 | 0.61222862918 |
| 15063893 | 3 | 0.206242553891 |
| 15063893 | 5 | 0.212584925376 |
| 15063893 | 9 | 0.151032524941 |
| 15063893 | 10 | 0.394466895351 |
| 15063893 | 12 | 0.0303218762795 |
| W02012089318 | 3 | 0.125676407303 |
| W02012089318 | 5 | 0.209781186736 |
| W02012089318 | 9 | 0.0317595709613 |
| W02012089318 | 10 | 0.620224259817 |
| W02016133879 | 3 | 0.24565231755 |
| W02016133879 | 4 | 0.0347372618494 |
| W02016133879 | 5 | 0.191988894743 |
| W02016133879 | 9 | 0.0632224949611 |
| W02016133879 | 10 | 0.282114183257 |
| W02016133879 | 12 | 0.170633341513 |
| + | + | ++ |

- High-Relevance Topic Areas
 - Topic 10
 - Topic 5
- Very similar Topic profiles

14469221, Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device, Roche Diagnostics, 2014

WO2012089318A1, Methods of selecting diabetes therapy regimens, Roche Diabetes, 2012
WO2016133879A1, Method, system and computer readable medium for assessing actionable
plycemic risk. U Virginia, 2016

15063893, Method and system for recommending a set of insuling dosages for a patient, Quattro Folia Oy, 2017



TEQMINE Created 15 Topic Areas

reservoir
actuator pump

where the properties of the properties of the point of the

element injection
delivery arranged
assembly syringe device
movement means human
dispensing proximal drive container
rotation des part cap drug
figure setting holder
body button surface relative
sorring piunger force unit needle axial
sleeve mechanism asp28
member
housing
cartridge

levels configured analyte
data sensors electronics temperature response signal concentration response working unit measurements device threshold strip control method measurement disensitivity sensors electronics temperature device temperature device temperature device temperature device temperature device threshold control method measurement disensitivity sensor control values sensing monitor level ochange rate meter period blood display system display

disease

agent device

purification by the second device

specification of the second device

effect of the solution of the second device of the second device

Topic 4

Topic 1

Topic 2

Topic 3

electrically electrode
therapy connected circuit
components element impedance signals

POWET be abody magnetic material system
generator be electric coil control system impodation system
generator be electric coil control system impodation signal eleade xternal figure energy implanted
electrical conductive stimulation voltage implantable

Topic 6

electrodes

Topic 7

medical delivery received system infusion system computer sensor roperation patient users unitsignal receive control mode wireless insulin screen electronic tage controller storage input mobile rfid data communications information network communication

Topic 5

respiratory vessel sympathetic system stimulation subject low rate cardiac low disease renal vascular fluid figure signal activity on nerveleft control period arterial volumelevel carotid delivery heart ablation artery parameters perfusion patients patient treatment

material plate reaction collection figure acid chemical protein target capillarysingle substratedna biological layer fluid ochip zone flow method binding reagent solution

Topic 8

antibody analyte

vesseldetection



TEQMINE Created 15 Topic Areas

subject
based signals
computer parameter patient
memory
brain
threshold
rate set set set learn configured configured disease sequence individual activity methods user input heart condition sleep sensors signal wearable method motion determining parameters

signal wearable method determining parameters
physiological information

Topic 9

surface delivery drugtherapeutic lumen actheter acid metal catheter layer polymer tissue release polymer growth matrix of growth

Topic 13



Topic 10

pharmaceutical adhesive substance figure agent ayer agent concentration particles drug applied powder contact surfacewater electrodes layers film amount acid ion substrate current liquid microneedles air microneedle administration material solution suitable formulation reservoir polymer membrane

Topic 14

optical light


systemtissuepower target
wavelength energy surface portion
image led emitting fiber intensity
laser probe sensor emitted imaging
beam wavelengths thermal nm
treatment figure radiation signal
sources detector measurement
blood reflected illumination
configured device eye
contact lens detection
absorption

temperature

Topic 11

patient structure method so tube treatment tube treatment tube treatment wall length of stomach wall length of sto

Topic 15



High Client
Interest Area
Topic



High Priority Topic Areas








- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- **Topic 5:** Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database

Total Patenting - Diabetes Map

2002-2017 (september)


Records By Publication Year



 C.a. 6000 patents / year and sligthly increasing patenting in the technology area



Topic Size by Patenting Diabetes




Topic 1 and 2 are largest



Total Patenting - Diabetes Map

2002-2017 (september)




- Topic 10 is a major growth area
- Topic 5 is recent major growth area



Total Patenting - Diabetes Map


Priority Topic Areas 2002-2017 (september)



- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- **Topic 5:** Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database



Diabetes Patent Map






Diabetes Patent Map

delivery

medical delivery
received system
module based displaycomputing
computer sensor foperation patient
users unitsignal receive
control mode wireless Suser
memory electronic tago configured
software rate software rate obattery
mobile frid power
communication information
network
communication

Topic 5







Priority Topic Areas in Detail

- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- Topic 5: Medical Device Data Communication User Wireless interface
- Topic 10: Patient Health Information User Data Healthcare Software Database





Topic 3 in Detail


Patenting activity and leading firms

method measurement describing values change determine values change described blood display system calibration insulintest

- High growtn 2005-2010, but currently stabilized.
- Average patenting 300 / year
- Leading inventors are large medical equipment and healthcare firms specialized in Diabetes care, e.g. DexCom, Akray, Medtronic, etc.
- Univ of Virginia holds significant patent portfolio
- Leading firms have very sizable patent portfolios > 100 patents
- Inventors concentrated in the US, GP, JP, IL, DE, KR, CH.








Topic 3 in Detail IPC focus



- A61B 5/00 Measuring for diagnostic purposes
- A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
- G06F 19/00 Digital computing or data processing equipment or methods, specially adapted for specific applications
- GO1N 27/00 Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY





Topic 5 in Detail

Patenting activity and leading firms


0

2002


2004

2006

- High growth in inventive and patenting effort, expect around 600 / year
- Leading inventors are large medical equipment and healthcare firms specialized in Diabetes care, but include also Samsung
- Leading firms have very sizable patent portfolios > 100 patents
- Inventors concentrated in the US, DE, GB, CH.
- Finland among top 15 countries



medical delivery received splaycomputing computer sensor reperation patient control mode wireless insulin screen memory electronic tage controllerstorageinput data communications information network communication



2008




2012

2014

2016


2010



Topic 5 in Detail IPC focus

medical delivery received delivery received delivery received system infusion system infusion system module based display computing computer sensor fooperation patient users unitsignal receive unitsignal receive control mode wireless unitsignal receive memory electronic tag configured controller stordivare rate obattery data communications information network communication

- A61B 5/00 Measuring for diagnostic purposes
- A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
- G06F 19/00 Digital computing or data processing equipment or methods, specially adapted for specific applications
- GO1N 27/00 Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- G06Q 50/00 Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G08B 23/00 Alarms responsive to unspecified undesired or abnormal conditions
- A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY





Topic 5 in Detail

Example Patent





Secure pairing of ehealth devices and authentication of data using a gateway device having secured a

Abstract

A gateway device, method for operating the gateway device, and system are presented for securely obtaining health information from a personal medical device. The method comprises receiving a gateway application from a relying system, storing the gateway application, executing the gateway application. The executing the gateway application comprises establishing first secure communication with the personal medical device, establishing second secure communication with the relying system, receiving information from the personal medical device via the first secure communication, transmitting the information to the relying system via the second secure communication.

Images (4)






The PMDs 104 may be sensors for reporting on the heart rate, blood pressure, blood sugar level, or other measurable characteristic of a user's body. The PMDs 104 may also be actuators for dispensing insulin, electrical stimulation, or other therapeutic action. A PMD may also be referred to as an eHealth device. A PMD may include a health sensor/actuator application that uses a sensor/actuator driver, a hardware security module, and a communication module to provide its functionality in cooperation with an external device. A PMD typically has little or no direct user interface functionality, relying, instead on the external device for such functionality.


Topic 10 in Detail


Patenting activity and leading firms

nutritional production interface Eigure clinical set or module services record storage food interface Eigure clinical set module network database services management eiger food individual network management eiger food individual network database services management eiger food individual network database patients spatients food individual network database patients food individual network database patients

- High growth in recent years, but has stabilized
- Expect around 600 patents / year
- Leading inventors are established software firms, large medical equipment and healthcare firms, as well as known patent trolls
- Leading firms have mid-size patent portfolios > 50 patents
- Inventors concentrated in the US, JP, CA, GB, DE, IL, NL








Topic 10 in Detail IPC focus



- A61B 5/00 Measuring for diagnostic purposes
- A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
- G06F 19/00 Digital computing or data processing equipment or methods, specially adapted for specific applications
- GO1N 27/OO Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- G06Q 50/00 Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G08B 23/00 Alarms responsive to unspecified undesired or abnormal conditions
- Topic Area technology is more IT and software driven





Topic 10 in Detail

Example Patent

WO2017096102 (A1) - DEVICES, METHODS, AND COMPUTER MEDIUM TO PROVIDE REAL TIME 3D VISUALIZATION BIO-FEEDBACK

HORSEMAN SAMANTHA J [SA]; GILLIGAN LINDA [SA] +

SAUDI ARABIAN OIL CO [SA]; ARAMCO SERVICES CO [US] +

- international: G06F19/00

- cooperative: G06F19/321; G06F19/3406; G06F19/3431; G06F19/3437; G06F3/04815; G06F3/04842;

G06T7/0016; G06T2200/24; G06T2207/30004; G06T2210/41

Description of the Related Art

[0002] In view of chronic health problems facing employees, employers may adopt workplace strategies to motivate and coach employees to improve their health and well- being. For example, diabetes may affect twenty percent (20%) of some populations. As will be understood by those skilled in the art, there exist a group of non-communicable diseases labeled "the big five": diabetes, cardiovascular disease, respiratory disease, cancer, and obesity. Research indicates that lifestyle is a contributing factor to the big five non-communicable diseases and may account for as much as eighty percent (80%) of the causes of these diseases.




Technology Focus Areas in Detail


- "Machine Learning" OR "Artificial Intelligence"
- "Pre-diabetic" Preventive care
- Diabetes-2
- Diabetic Eye Conditions




Machine Learning - AI

- DESCRIPTION: "machine learning" OR "artificial intelligence"
 - 3158 patents
- VERY HIGH growth, expect 200 / 2017, and continued high growth
- Leading patent firms large software firms, specialized health-care software firms, and starupts.









Machine Learning – AI – Example patent

<u>US2017143279 (A1) - DEVICE AND METHOD TO DETECT DIABETES IN A PERSON USING PULSE PALPATION SIGNAL</u>


JAYARAMAN SRINIVASAN [IN]; THOKALA NAVEEN KUMAR [IN]; PURUSHOTHAMAN BALAMURALIDHAR [IN] +

TATA CONSULTANCY SERVICES LTD [IN] ±

Abstract of US2017143279 (A1)


Translate this text into
Select language
patenttranslate powered by EPO and Google


A device and method is provided for the detection of diabetes in a person using pulse palpation signals. The pulse palpation signal is captured from the radial artery of the person using a photo-plethysmograph (PPG) sensor. The PPG signal is then preprocessed by a processor. The preprocessed PPG signal is then analyzed by the processor to detect the peak in the PPG signal. The detected peaks are used to extract a first set of feature parameters. The first of feature parameters are compared with a second set of feature parameters, wherein the second set of feature parameters are extracted from the control group of individuals. Based on the comparison it is detected that the person is one of in normal condition, pre-diabetic condition or a diabetic condition. According to another embodiment, the invention also provides a method to determine the severity index and progression risk of diabetes in the person.




Pre-Diabetic – Early Stage Diagnosis

- **DESCRIPTION**: "pre-diabetic" OR "pre diabetic" OR "early detection ..."
 - 391 patents
 - MYLIST: "pre-diabetic_2"
- RELATIVELY SMALL PATENT AREA, BUT
- RAPIDLY EMERGING TECHNOLOGY AREA, with high growth. Currently around 60 / year and continued high growth
- FITBIT the leading patent firm, followed by mixed group of specialized medical equipment and software firms.
 Universities also pay an important role.








IPC focus of Pre-Diabetic

- A61B 5/00 Measuring for diagnostic purposes
- A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
- G06F 19/00 Digital computing or data processing equipment or methods, specially adapted for specific applications
- GO1N 27/00 Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- Diagnostic technologies mixed with software and computing technologies





Pre-Diabetic – Example Patents

<u>US2017277841 (A1) - SELF-LEARNING CLINICAL INTELLIGENCE SYSTEM BASED ON BIOLOGICAL INFORMATION AND MEDICAL DATA METRICS</u>

SHANKAR SUSHANT [US]; DASH RAJESH [US]; DESAI NIKHIL [US]; FU JUSTIN JUNXUAN [US] ±

HEALTHPALS INC [US] +

Biological information and medical knowledge information are used for self-learning clinical intelligence. Medical knowledge information is assembled. Medical rules are generated based on the medical knowledge. The medical rules can be generated probabilistically. A plurality of risk models can be learned. The plurality of risk models are associated with a given disease based on patient attributes. A medical probabilistic rule graph is built based on the medical rules and the plurality of risk models. The building of the medical probabilistic rule graph is based on ordering the medical rules. Attributes from an individual patient are applied to the medical probabilistic rule graph. A diagnosis for the individual is generated from the attributes applied to the medical probabilistic rule graph. A treatment for the individual can be generated from the attributes applied to the medical probabilistic rule graph.

[0040] The flow 100 can include building risk models 132. Risk models are based on medical knowledge information and related to medical rules, but the risk models focus on medical metrics and biological information that combine to indicate probabilistically certain medical risks. For example, the current best knowledge risk factors for heart disease include high blood pressure, high blood cholesterol, diabetes and prediabetes, smoking, being overweight or obese, being physically inactive, having a family history of early heart disease, having a history of preeclampsia during pregnancy, unhealthy diet, and age (55 or older for women). A risk model can be built using the known risk factors with a probabilistic traversal of the risk model, that is, factors A, B, C, and D may yield a higher risk than factors A, B, C, and E, for example. In addition, the risk models may include exposing the actual risk (well understood and accepted), exposing risk contributors (novel), and exposing what-if simulation (very novel) to provide clinical intelligence over a broader spectrum of possibilities than is normally available in a clinical setting. The risk models can be included in the building a medical probabilistic rule graph 130. In embodiments, the risk models can be included in the building a medical probabilistic inference graph.




Pre-Diabetic – Example Patents

<u>US2017277841 (A1) - SELF-LEARNING CLINICAL INTELLIGENCE SYSTEM BASED ON BIOLOGICAL INFORMATION AND MEDICAL DATA METRICS</u>

SHANKAR SUSHANT [US]; DASH RAJESH [US]; DESAI NIKHIL [US]; FU JUSTIN JUNXUAN [US] +

HEALTHPALS INC [US] +





Pre-Diabetic – Example Patents

WO2017136218 (A1) - SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.





Company



dexcom.com

Dexcom, Inc. is a company that develops, manufactures and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California, United States. Wikipedia

Stock price: DXCM (NASDAQ) US\$50,74 +0,36 (+0,71 %)

10 Nov. 16.00 GMT-5 - Disclaimer

Headquarters: San Diego, California, United States

CEO: Kevin R. Sayer CFO: Quentin Blackford

Founded: 1999


EVP: Andrew K. Balo (Clinical, Regulatory, Global Access), MORE


Subsidiaries: Nintamed GmbH & Co. KG, SweetSpot Diabetes Care,

Inc., DXCM Sweden AB

Type-2 Diabetes

- DESCRIPTION: "diabetes mellitus type 2"
 OR "diabetes type 2" OR "diabetes type 2" OR "type 2 diabetes" OR "type-2 diabetes"
 - 4130 patents
- RELATIVELY LARGE PATENT AREA, with stabilized growth. Expect 120 patents / 2017, and continued growth
- Leading patent firms large software firms, specialized health-care software firms, and starupts.
- Includes large group of patents dealing with "life style" issues










IPC focus of Type-2 Diabetes

- A61B 5/00 Measuring for diagnostic purposes
- A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
- G06F 19/00 Digital computing or data processing equipment or methods, specially adapted for specific applications
- GO1N 27/00 Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- Diagnostic technologies mixed with software and computing technologies





Type 2 Diabetes - Example Patents

US2017293733 (A1) - Dynamic Selection and Sequencing of Healthcare Assessments for Patients

KELLY KARIE L [US]; KUMAR ATUL [US]; MCCOY ADAM C [US]; MRNUSTIK GUY B [US]; OLSEN RUSSELL G [US]; WALTERS PATRICK L [US] ±

IBM [US] +


- international: G06F17/27; G06F19/00

[0035] It should be appreciated that the term "lifestyle" as it is used herein refers to the way in which a person lives their lives. The term "lifestyle information" refers to the data collected that characterizes the lifestyle of the patient and may encompass various temporal, spatial, environmental, and behavioral information/data about the patient that together comprises a unique combination of information/data that characterizes and represents the way in which that specific patient conducts their life on a daily basis. The lifestyle information for a patient is specific to that patient and is not generally applicable to multiple patients. The lifestyle information may be provided at various levels of granularity depending upon the particular implementation. As part of this lifestyle information, data generated by the specific patient via one or more computing devices or other data communication devices may be included such as actions performed by the patient on a daily basis, personal schedules, specifications of preferences, etc. For example, lifestyle information may include the patient entering information, such as into a computing device executing a patient tracking application, indicating that the patient ate breakfast at a fast food restaurant in the airport on the way to Virginia this morning. In addition, data generated by external systems associated with third parties that characterizes the patient's lifestyle may be included in the lifestyle information as well, e.g., a healthcare insurance company may have information about the patient's lifestyle.




Diabetic Eye


- CLAIMS: "diabetic macular" OR "diabetic retinopathy" OR "diabetic eye"
 - 181 patents
- NOTE: Diabetic eye is very large patenting area focussing on treatment (esp drug delivery) and evaluation. Search limited to patents with related claims to narrow patents to reasonable number.
- Technologically separate area from other technology areas analyzed here
- Leading countries. US, GB, IL, CH, AU, DK, FR, CN, DE.












Diabetic Eye

- A61B 3/00 Apparatus for testing the eyes; Instruments for examining the eyes
- A61B 3/12 for looking at the eye fundus, e.g. ophthalmoscopes
- A61B 3/14 Arrangements specially adapted for eye photography
- A61B 3/10 Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
- A61B 5/00 Measuring for diagnostic purposes





Diabetic Eye – Example Patent

Treatment and prevention of retinal vascular disease by photocoagulation

Abstract

This disclosure relates to methods for treatment or prevention of retinal vascular disease by photocoagulation. More specifically, this disclosure relates to an improved technique for the placement of retinal burns so as to prevent the development of hypoxia and progression of ischemia in retinal tissue, including the macula. The methods can also be employed to prevent potential ischemic tissue damage in diabetic, pre-diabetic or other patients with ischemic retinal vascular disease, or those at risk of ischemic retinal vascular disease.


Classifications

VP 4 VI P VI

A61F9/00821 Methods or devices for eye surgery using laser for coagulation

W02017127732A1

WO Application



Other languages: French

Inventor: Thomas J. GAST, Xiao FU

Original Assignee: Indiana University Research And

Technology Corporation

Priority date: 2016-01-21




Major Firms in Detail


- Hoffman-La Roche Group
- Roche Diabetes
- Novartis
- Sanofi Aventis
- Medtronic
- Novo Nordisk
- Abbott Diabetes
- Dexcom




Roche Group in Detail

- Very strong and broad patent portfolio, covering different Diabetes areas.
- 1138 patents
- Main patent areas: Topic 1, 3, and 5.
- Technological and patenting focus is shifting from strategically
- Broad geographical base of inventors







Roche Group in Detail

- Topic Area distribution shows strategic focus
- Shiftings from one to other area
- Main interest areas part of main trends of the broader map data


| Topic | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|------|------|------|------|------|------|-------|
| 1 | 15 | 12 | 36 | 45 | 47 | 36 | 25 | 11 | 13 | 26 | 313 |
| 5 | 6 | 39 | 21 | 45 | 42 | 36 | 42 | 8 | 10 | 13 | 273 |
| 3 | 10 | 6 | 18 | 17 | 22 | 13 | 25 | 15 | 11 | 8 | 168 |
| 10 | 4 | 45 | 16 | 17 | 24 | 32 | 10 | 0 | 0 | 3 | 157 |
| 2 | 3 | 8 | 2 | 13 | 3 | 7 | 8 | 1 | 1 | 7 | 55 |
| 8 | 1 | 0 | 0 | 0 | 5 | 8 | 11 | 3 | 2 | 1 | 49 |


- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- **Topic 5:** Medical Device Data Communication User Wireless interface
- Topic 10: Patient Health Information User Data Healthcare Software Database



Roche Diabetes in Detail

- A new entity with clear technology and business focus
- 85 patents
- Strongly growing patenting activity
- Main patent areas: Topic 1, 3, and 5.
- Technological and patenting focus is shifting from strategically
- Broad geographical base of inventors







Roche Diabetes in Detail

- Topic Area distribution shows strategic focus
- Main effort in Topic Area 1, 3, and 5

| Topic | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|-------|
| 1 | 0 | 0 | 7 | 23 | 29 |
| 3 | 0 | 5 | 8 | 7 | 20 |
| 5 | 0 | 0 | 6 | 13 | 19 |
| 2 | 0 | 0 | 0 | 3 | 3 |
| 12 | 0 | 1 | 1 | 1 | 3 |
| 13 | 0 | 0 | 2 | 0 | 2 |
| 10 | 0 | 0 | 0 | 2 | 2 |


- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- Topic 5: Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database




Novartis in Detail

- Small portfolio, but increasing
- 39 patents
- Patenting too small volume to support 6 clear conclusions






Top 10 Countries By Inventors



Sanofi-Aventis in Detail

- Very large patent portfolio, but decreasing patent effort
- 1908 patents
- Very narrow technology and patent focus as analyzed in IPC and Topic Areas
- Main Focus Area Topic 2, IPC A61M5





Sanofi-Aventis in Detail


| Topic | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|------|------|------|------|------|------|-------|
| 2 | 12 | 12 | 134 | 184 | 429 | 343 | 251 | 189 | 156 | 83 | 1,799 |
| 1 | 0 | 1 | 2 | 7 | 33 | 20 | 29 | 3 | 0 | 1 | 98 |
| 5 | 0 | 0 | 4 | 3 | 6 | 2 | 7 | 6 | 8 | 0 | 36 |
| 3 | 0 | 0 | 0 | 3 | 4 | 2 | 1 | 4 | 1 | 0 | 15 |
| 10 | 0 | 0 | 2 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 13 |
| 12 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 8 |
| 11 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 7 |
| 14 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 5 |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 3 |


- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- **Topic 5:** Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database



Medtronic in Detail

- Large portfolio, but increasing
- 1904 patents
- Patenting continues strong in emerging areas, such as Topic Areas 1, 3, 5.
- Broad technological focus, as evident in IPC and Topic Area Analysis





Medtronic in Detail


| Topic | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|------|------|------|------|------|-------|
| 1 | 34 | 36 | 59 | 72 | 38 | 37 | 22 | 12 | 7 | 449 |
| 5 | 29 | 31 | 39 | 36 | 16 | 8 | 18 | 11 | 13 | 320 |
| 3 | 15 | 25 | 34 | 22 | 23 | 19 | 20 | 1 | 10 | 242 |
| 6 | 34 | 9 | 56 | 15 | 11 | 8 | 4 | 4 | 2 | 224 |
| 7 | 4 | 12 | 9 | 28 | 35 | 30 | 19 | 6 | 6 | 193 |
| 15 | 6 | 11 | 9 | 25 | 16 | 9 | 23 | 1 | 0 | 167 |


- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- Topic 5: Medical Device Data Communication User Wireless interface
- Topic 10: Patient Health Information User Data Healthcare Software Database



Novo Nordisk in Detail

- Large portfolio, and relatively stable patent effort.
- Currently probably increasing.
- 805 patents
- Technologically relatively narrow focus





Novo Nordisk in Detail


| Topic | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total → |
|-------|------|------|------|------|------|------|------|------|------|---------|
| 2 | 25 | 26 | 12 | 17 | 31 | 44 | 40 | 42 | 34 | 394 |
| 1 | 22 | 14 | 12 | 11 | 9 | 8 | 8 | 9 | 4 | 232 |
| 5 | 8 | 7 | 1 | 1 | 3 | 2 | 0 | 3 | 0 | 72 |
| 14 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 32 |
| 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
| 10 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 16 |

- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- Topic 5: Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database



Abbott Diabetes in Detail

- Large portfolio, but strongly declining inventive effort
- 1185 patents
- Technologically relatively narrow focus per IPC and Topic Area classification



Abbott Diabetes in Detail


| Topic | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|------|------|------|------|------|------|------|-------|
| 3 | 38 | 84 | 120 | 135 | 71 | 56 | 42 | 62 | 29 | 28 | 18 | 688 |
| 5 | 2 | 19 | 19 | 41 | 30 | 20 | 16 | 43 | 25 | 12 | 9 | 238 |
| 1 | 6 | 8 | 21 | 44 | 24 | 15 | 5 | 4 | 3 | 1 | 1 | 132 |
| 14 | 9 | 9 | 7 | 20 | 10 | 8 | 7 | 13 | 4 | 1 | 0 | 89 |
| 10 | 0 | 0 | 0 | 3 | 9 | 1 | 0 | 1 | 0 | 0 | 1 | 15 |
| 6 | 2 | 0 | 2 | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 11 |
| 8 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 7 |
| 2 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 4 |
| 15 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |

- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- Topic 5: Medical Device Data Communication User Wireless interface
- Topic 10: Patient Health Information User Data Healthcare Software Database



Dexcom in Detail

- Large portfolio, but strongly declining inventive effort
- Topic Area 5 is a modest, and only real, growth area (mobile & wireless devices)
- 577 patents
- Technologically relatively broad focus per IPC and Topic Area classification



Dexcom in Detail

| Topic | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Total |
|-------|------|------|------|------|------|------|------|------|------|------|-------|
| 3 | 41 | 63 | 103 | 53 | 55 | 30 | 65 | 7 | 13 | 7 | 494 |
| 14 | 0 | 2 | 1 | 4 | 2 | 5 | 3 | 0 | 0 | 4 | 28 |
| 5 | 0 | 0 | 0 | 1 | 0 | 1 | 10 | 3 | 4 | 6 | 27 |
| 13 | 3 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 0 | 0 | 15 |
| 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 2 | 6 |
| 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 |

- Topic 3: Sensor Measuring Data Glucose Insuling Blood
- **Topic 5:** Medical Device Data Communication User Wireless interface
- **Topic 10:** Patient Health Information User Data Healthcare Software Database





CONTACT

Hannes Toivanen

Tel. +358 50 400 2947 Email. Hannes.Toivanen@teqmine.com

Pasilanraitio 5 00240 Helsinki Finland www.teqmine.com